ELMWOOD PARK, N.J.--(BUSINESS WIRE)--At the National Society of Genetic Counselors meeting in San Diego, CA today, GenPath Women’s Health, one of the leading Women’s Health laboratories in the United States in collaboration with GeneDX, one of the leading genetic laboratories in the world specializing in rare genetic disorders, and both divisions of BioReference Laboratories, Inc. (NASDAQ - BRLI), announced a groundbreaking genetic screening test that will identify more than 550 mutations in over 160 diseases. The Pan-Ethnic Carrier Screen is a simple blood test and will be the most comprehensive genetic screening test offered by any laboratory; it will allow individuals from at-risk groups, as well as individuals who are unsure if they are at-risk, to determine the likelihood of dangerous genetic mutations being passed on to their children. Offered primarily through GenPath Women’s Health which has contracts with most national insurance plans, the test will be offered by the patient’s physician, obstetrician or genetic counselor during the first trimester or prior to conception.
